Imatinib (QTI571) in Pulmonary Arterial Hypertension
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
A multinational, multicenter, double blind, placebo-controlled study evaluating the efficacy
and safety of imatinib as an add-on therapy in the treatment of patients with severe
pulmonary arterial hypertension (PAH).